The earnings call highlights several concerns, including regulatory and competitive risks, supply chain challenges, and funding issues for the CLS-AX Phase 3 program. Although there are promising developments like regulatory milestones and collaborations, the lack of clear financial guidance, potential funding shortfalls, and management's vague responses in the Q&A suggest uncertainty. The absence of a shareholder return plan and potential economic impacts further contribute to a negative sentiment. These factors likely lead to a stock price decline, especially given the competitive pressures and financial constraints.
Attend Webcast